A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

Inclusion Criteria Concurrent Medication: Allowed with caution: * Acyclovir. * Famciclovir. * Valaciclovir. * Imipenem-cilastatin. * Myelosuppressive agents. Patients must have: * HIV infection with CMV retinitis. * Minimum of 4 weeks prior treatment with ganciclovir, foscarnet, or cidofovir. * Intraocular implant in either or both eyes, as long as CMV retinitis is active in one eye, upon approval by Roche. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms of conditions are excluded: * Active extraocular CMV disease. * Severe uncontrolled diarrhea or evidence of malabsorption. Concurrent Medication: Excluded: * Foscarnet. * Cidofovir. * CMV hyperimmune globulin. * Probenecid. Patients with the following prior conditions are excluded: * Ocular media opacities (corneal, aqueous, lens, or vitreous) preventing ophthalmologic retinal assessment. * Simultaneous participation in another study (unless approved by Roche). Required: * A minimum of 4 weeks treatment with ganciclovir, foscarnet, or cidofovir. * Approval required for prior use of investigational anti-CMV agents.